Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Taylor, Walter R J ^a,b   Thinh, Bui Nghia ^c   Anh, Giang Thuc ^c   Horby, Peter ^a,b   Wertheim, Heiman ^a,b   Lindegardh, Niklas ^b,d   de Jong, Menno D ^a,b   Stepniewska, Kasia ^b,d   Hanh, Tran Thuy ^c   Hien, Nguyen Duc ^e   Bien, Ngo Minh ^c   Chau, Ngo Quy ^c   Fox, Annette ^a,b   Ngoc, Nghiem My ^a   Crusat, Martin ^a   Farrar, Jeremy J ^a,b   White, Nicholas J ^b,d   Ha, Nguyen Hong ^e   Lien, Trinh Thi ^e   Trung, Nguyen Vu ^e   Day, Nicholas ^b,d   Binh, Nguyen Gia ^c   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c BACH MAI HOSPITAL   (Viet Nam)

^d MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^e National Institute for Infectious and Tropical Diseases   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIBIOTIC AGENT; DRUG METABOLITE; HYDROCORTISONE; OSELTAMIVIR; SIALIDASE; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL PNEUMONIA; BLOOD; CASE REPORT; CONTINUOUS HEMOFILTRATION; CREATININE CLEARANCE; DEATH; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS A H5N1; KIDNEY FAILURE; MALE; NASOGASTRIC TUBE; NONHUMAN; NOSE; RECTUM; RESPIRATORY FAILURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEADY STATE; THROAT; TRACHEA; VIRUS ISOLATION; VIRUS LOAD; CLINICAL TRIAL; DIGESTIVE TRACT INTUBATION; HEMOFILTRATION; METABOLISM; PREGNANCY; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; AREA UNDER CURVE; FEMALE; HEMOFILTRATION; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; INTUBATION, GASTROINTESTINAL; MALE; OSELTAMIVIR; PREGNANCY; RESPIRATION, ARTIFICIAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 54849438704     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003410     Document Type: Article

References (24)

1. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, et al. (2005) Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 353: 1374-1385.
2. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, et al. (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358: 261-273.
3. WHO (2006) Epidemiology of WHO confirmed cases of avian influenza A (H5N1) cases. WER 81: 249-260.
4. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, et al. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-1188.
5. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
6. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
7. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, et al. (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 163: 1667-1672.
8. Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, et al. (2007) WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 7: 21-31.
9. He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37: 471-484.
10. Schentag JJ, Hill G, Chu T, Rayner CR (2007) Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharm 47: 689-696.
11. Abe M, Smith J, Urae A, Barrett J, Kinoshita H, Rayner CR (2006) Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann Pharmacother 40: 1724-30.
12. Snell P, Nisha D, Wilson K, Rowell L, Weil A, et al. (2005) Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. B J Clin Pharmcol 59: 598-601.
13. Robson R, Buttimore A, Lynn K, Brewster M, Ward P (2006) The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 21: 2556-2562.
14. Gruber PC, Tian Q, Gomersall CD, Joynt GM, Choi GYS (2007) An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration. Int J Antimicrob Agents 30: 95-97.
15. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA (2007) Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir. EID 13: 1354-1357.
16. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, et al. (2006) Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob Agents Chemother 50: 3809-3815.
17. Chapman MJ, Nguyen NQ, Fraser RJ (2007) Gastrointestinal motility and prokinetics in the critically ill. Curr Opin Crit Care 13: 187-194.
18. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, et al. (2005) Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352: 686-691.
19. Lindegårdh N, Davies GR, Hien TT, Farrar J, Singhasivanon P, et al. (2007) Importance of collection tube during clinical studies of oseltamivir. Antimicrob Agents Chemother 51: 1835-1836.
20. Lindegårdh N, Davies GR, Tran TH, Farrar J, Singhasivanon P, et al. (2006) Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterases. Antimicrob Agents Chemother 50: 3197-3199.
21. Lindegårdh N, Hanpithakpong W, Wattanagoon Y, Singhasivanon P, White NJ, et al. (2007) Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. J Chromatogr B Analyt Technol Biomed Life Sci 859: 74-83.
22. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12: 1203-1207.
23. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A (2003) Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47: 2264-2272.
24. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, et al. (2006) Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrob Agents Chemother 50: 2395-2402.